Thank you for subscribing!
Wise-Owl Jun 26, 2023
BOD Science (ASX:BOD) has shifted gears from slowly growing revenue, in favour of going for a big blue sky approach to delivering shareholder outcomes. With two near term catalysts on the horizon, could this be the time for BOD?
Wise-Owl Mar 24, 2023
There have not been any CBD products approved yet for OTC sale in pharmacies - yet. However our sub-$10M capped cannabis Investment BOD Science (ASX:BOD) is keen to be first to enter the national market.
Wise-Owl May 20, 2022
BOD has just began two clinical trials, we are hoping for a re-rate on results of these trials. BOD dosed the first patients for the following trials in the last month for Insomnia (Phase 2b) and Long-COVID (Open label).
Next Investors Jun 17, 2021
Today Creso Pharma (ASX: CPH | OTC: COPHF) announced its plans to merge with a Canadian listed psychedelics company called Red Light Holland.
Get expert stock analysis direct in your inbox
Finfeed Archived Jun 11, 2021
The US OTC listing gives Creso Pharma Ltd (ASX: CPH) greater exposure to a deeper capital market as well as greater access and liquidity for North American investors. Further to this, it provide additional opportunities to attract institutional and retail investors and for CPH to expand its investor base in the US.
Catalyst Hunter Archived May 05, 2021
Neurotech International Ltd (ASX: NTI) has begun its first clinical trials on children aged between 5 and 17 years with Autism Spectrum Disorder (ASD) for its unique cannabis strain.
Finfeed Archived Apr 30, 2021
There were several highlights to come out of the quarterly report released by Creso Pharma (ASX: CPH) today. CPH is enjoying a sustained run this year with revenues up 237% in the lead up to its US listing, which is expected to occur in the coming weeks.
Finfeed Archived Apr 22, 2021
Medicinal cannabis, CBD and hemp healthcare products company, Bod Australia Limited (ASX: BDA) has provided its shareholders an update for the Q3FY2021 quarter, ended 31 March 2021.
Finfeed Archived Mar 31, 2021
Creso Pharma’s (ASX: CPH) pending acquisition of Halucenex Life Sciences should prove to be an astute move, with Halucenex continuing to rapidly move towards its goal of developing and licensing psychedelic compounds for the pharmaceutical and nutraceutical markets.
Finfeed Archived Mar 26, 2021
Creso Pharma (ASX: CPH) has received firm commitments to raise $18M, a sum that significantly shores up its balance sheet. CPH will use the funds to progress a number of value accretive opportunities including Phase II and Phase III clinical trial initiatives with target acquisition company Halucenex Life Sciences Inc.
Finfeed Archived Mar 23, 2021
Creso Pharma (ASX: CPH) today announced it is listing on the OTC market in the USA. Listing on the OTC is expected to unlock significant shareholder value and provides CPH with access to one of the largest investment markets in the world at nominal cost.
Finfeed Archived Mar 17, 2021
Bod Australia (ASX: BDA) is a cannabis centric healthcare company, with well-branded premium, proven and trusted products within two distinct verticals: Medical Cannabis and CBD and Hemp Consumer products.
Finfeed Archived Mar 09, 2021
Neurotech International Limited (ASX: NTI) has announced a strategic cultivation partnership with CannaPacific Limited to grow and maintain genetic stock and assist in the development of elite varietal strains through their exclusive licencing agreement.
Finfeed Archived Feb 15, 2021
Following the successful in vitro findings, Neurotech (ASX: NTI) has begun designing a phase I/II study to assess the safety and efficacy of the novel NTI/Dolce strain in a paediatric population.
Next Investors Jan 19, 2021
Today Creso Pharma (ASX: CPH) reported new and follow up Purchase Orders for its animal health medicinal cannabis products totalling over A$345,000.
Catalyst Hunter Archived Dec 16, 2020
Neurotech International Ltd (ASX: NTI) is focused on the clinical applications of unique cannabis strains to treat neurological disorders such as autism and is set to commence human clinical trials early in 2021.
Finfeed Archived Dec 11, 2020
Creso Pharma Limited (ASX:CPH, FRA:1X8) has today announced obtainment of an exclusive Heads of Agreement with leading natural, sustainable health and lifestyle brand supplier Martin & Pleasance Pty Ltd.
Finfeed Archived Sep 10, 2020
The TGA has recommended that CBD products be down-scheduled to schedule 3 medicines in Australia, allowing OTC sales, which should benefit Creso Pharma (ASX: CPH).
Join Our Mailing List
